Fig. 1.

NK-mediated lysis of prostate carcinoma cells is increased following exposure to olaparib. a Real-time impedance-based cell analysis of BRCA mutant prostate carcinoma (22RV1) cells in the presence or absence of olaparib (ola) and NK. b Lysis of BRCA mutant cells treated with or without olaparib and NK compared to control at 12 h and 36 h. c Real-time impedance-based cell analysis of BRCA WT prostate carcinoma (DU145) cells in the presence or absence of olaparib and NK. d Lysis of BRCA WT cells treated with olaparib and NK compared to control at 12 h and 36 h. These experiments were performed with four different human NK donors with similar results. p < 0.01**, p < 0.001***, p < 0.0001****